---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001016"
form_type: "8-K"
ticker: "CBIO"
cik: "0001253689"
company_name: "CRESCENT BIOPHARMA, INC."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T19:24:21.078364+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities

## Summary
- Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.
- Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.
- A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.
- Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.
- Condition: GLYC net cash at closing must be ~$1.8M.

## SEC filing metadata
- accession: 0001558370-25-001016
- form_type: 8-K
- ticker: CBIO
- cik: 0001253689
- company_name: CRESCENT BIOPHARMA, INC.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/0001558370-25-001016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/glyc-20250214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001016
- JSON: https://secwatch.observer/filing/0001558370-25-001016.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.